Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Tells Court Cipla Fight Not ‘Public-Interest Litigation’

This article was originally published in PharmAsia News

Executive Summary

A lawyer for F. Hoffman-La Roche, a Swiss drug maker, says the lawsuit it is pressing against India's Cipla should not be considered a matter involving the public interest. Roche has filed a suit to stop Cipla from marketing a generic of the Swiss company's Tarceva (erlotinib). Roche lost a motion for an injunction against Cipla on grounds it would have denied patients a drug costing only a third of the cost of Tarceva. The Roche attorney thus is arguing the company already was providing the drug free to patients referred by doctors to its "patient assistance programs," so the lack of access was not an issue. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts